- Home
- SITC vs PROK Comparison
SITC vs PROK Comparison
Compare SITC & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SITC
- PROK
- Stock Information
- Founded
- SITC 1965
- PROK 2015
- Country
- SITC United States
- PROK United States
- Employees
- SITC N/A
- PROK N/A
- Industry
- SITC Real Estate Investment Trusts
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SITC Real Estate
- PROK Health Care
- Exchange
- SITC Nasdaq
- PROK Nasdaq
- Market Cap
- SITC 391.8M
- PROK 417.1M
- IPO Year
- SITC 1993
- PROK N/A
- Fundamental
- Price
- SITC $7.30
- PROK $2.78
- Analyst Decision
- SITC Hold
- PROK Strong Buy
- Analyst Count
- SITC 4
- PROK 4
- Target Price
- SITC $12.63
- PROK $6.25
- AVG Volume (30 Days)
- SITC 1.1M
- PROK 1.5M
- Earning Date
- SITC 11-05-2025
- PROK 11-10-2025
- Dividend Yield
- SITC 79.04%
- PROK N/A
- EPS Growth
- SITC N/A
- PROK N/A
- EPS
- SITC 0.54
- PROK N/A
- Revenue
- SITC $139,962,000.00
- PROK $744,000.00
- Revenue This Year
- SITC N/A
- PROK $471.74
- Revenue Next Year
- SITC N/A
- PROK N/A
- P/E Ratio
- SITC $13.32
- PROK N/A
- Revenue Growth
- SITC N/A
- PROK N/A
- 52 Week Low
- SITC $6.89
- PROK $0.46
- 52 Week High
- SITC $16.51
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- SITC 24.88
- PROK 45.61
- Support Level
- SITC $6.89
- PROK $2.56
- Resistance Level
- SITC $7.48
- PROK $2.94
- Average True Range (ATR)
- SITC 0.19
- PROK 0.23
- MACD
- SITC -0.09
- PROK -0.05
- Stochastic Oscillator
- SITC 17.82
- PROK 25.41
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.